EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

BICO Group AB (publ) (BCCOY) fair value: what the stock is really worth

As of Sep 18, 2026: fair value of BICO Group AB (publ) $1.60, price $0.59, upside +172.5%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · Home Sweden

BG BICO Group AB (publ) logo Thin data Sep 24, 2026

BICO Group AB (publ)

BCCOY · US

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value $1.60 · Strongly undervalued (+173%)
!Quality 50/100
!Weak Growth (revenue 5y +51.4 %/yr)
!Loss-making · -66.1% net margin (TTM)
✓Low debt · generates free cash flow
!Mixed vs. peers (6/11)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch BICO Group AB (publ) for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.80 $0.3688 Fair Value $1.60 Sep 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.3688 – $14.80 · fair‑value band $1.19 – $1.74 · the $0.5871 price screens below the $1.60 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow BICO Group AB (publ) in your weekly email

Every Wednesday you see whether BICO Group AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation.

Show more

BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, build, and install automated laboratory systems. In addition, the company offers a range of services and consumables such as reagents, bioinks, plates, and tissue models. It serves pharma and biopharma, biotech, diagnostics, academia and research, and cosmetic industries. The company offers its products through sales organizations, as well as through distributor network. BICO Group AB (publ) was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. The company was incorporated in 2016 and is headquartered in Gothenburg, Sweden.

Stock analysis

BICO Group AB (publ) (BCCOY) currently trades at $0.5871, while our model-based Fair Value estimate is $1.60, implying the stock looks roughly 63.3% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $1.60 per share, and 6 of the 7 models we run sit above the $0.5871 price.

Bear case: the Asset-Based group reads lowest at $0.3859, and 1 of the 7 models stay below the price. Evidence for this calculation is low.

Scenario range: $1.19 (bear) to $1.74 (bull), the price of $0.5871 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

BICO Group AB (publ) reported revenue of 1.4B SEK in FY2025 versus 1.3B SEK in FY2021, a compound +2.9%/yr. Reported net income was −1.0B SEK in FY2025.

Key figures

Market cap $166M · P/S ratio 0.08 · EPS (TTM) $−0.5600 · Net margin −72.7% · Return on equity −69.3% · Return on assets (EBIT) −4.6% · Revenue (TTM) $1.8B · Revenue growth (YoY) −1.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 41% below its 52-week high and 57% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 173%, BCCOY screens cheaper than that median.

Fair Value models

Bear $1.19 Fair Value $1.60 Bull $1.74
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $1.56 $2.02 $3.35 75
Growth DCF $1.49 $2.14 $3.16 74
5Y Revenue Exit $0.9338 $1.11 $1.47 70
All 7 models by family
DCF Models
FCF DCF $1.56 $2.02 $3.35 75
5Y Revenue Exit $0.9338 $1.11 $1.47 70
10Y Revenue Exit $1.16 $1.60 $1.75 64
Multiples
EV/Revenue $0.5779 $0.6444 $0.7108 54
Asset-Based
NCAV (Graham) $0.2876 $0.3859 $0.5761 54
Growth DCF
Growth DCF $1.49 $2.14 $3.16 74
Rev-Margin DCF $0.9747 $1.21 $1.73 69

Open the full fair value analysis →

Notify me when BCCOY reaches fair value

Put BCCOY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 50/100

Of which business quality 50 · Market factors (momentum, volatility) 20

Profitability 9
Margins and returns on capital today
Quality Growth 29
Are margins and returns improving?
Cashflow 44
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 19
Distance to the 52-week high (market factor)
Net Issuance 83
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−27.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.4%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+79.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−37.4% (2020) → −16.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +5.1% a year for the forecasts.
Forecast 2026 (sales)+11.3%
Forecast 2027 (sales)+7.8%
Projected 2028 (sales)+7.1%
Projected 2029 (sales)+6.4%
Projected 2030 (sales)+5.6%

Watch BCCOY, get fair value alerts →

Compare BICO Group AB (publ) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside +173% · Top 25%
Profitability
Return on assets −4% · Below median
Net margin (TTM) −66% · Bottom 25%
Operating margin (TTM) 0% · Below median
Growth and dividend
Revenue growth −1% · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.09× · Cheapest 25%
P/S (TTM) 0.09× · Cheapest 25%
P/FCF 3.2× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 3
FUTURE (revenue growth)0 · sector 30
PAST (return on equity)0 · sector 5
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.69 $74.79 −28%
Stryker Corporation SYK $275.09 $302.60 +10%
Medtronic plc MDT $90.77 $65.57 −28%
Boston Scientific Corporation BSX $44.92 $49.41 +10%
Edwards Lifesciences Corporation EW $88.78 $82.04 −8%
Siemens Healthineers AG SHL €37.43 €35.22 −6%
DexCom, Inc DXCM $89.53 $98.48 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BICO Group AB (publ) · Fair Value
$1.60 +63%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "BICO Group AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/BCCOY

Frequently asked questions

Is BICO Group AB (publ) (BCCOY) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $1.60 versus a price of $0.5871, about +173% upside (undervalued).
What is the fair value of BCCOY?
Our model-based fair value for BICO Group AB (publ) is $1.60 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.5871.
What is the quality score of BCCOY?
BICO Group AB (publ) has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BICO Group AB (publ) (BCCOY)?
Our model-based price target is the fair value of $1.60 (as of Sep 24, 2026) from 7 valuation models. Cautious scenario $1.19, optimistic scenario $1.74. It is a calculation from audited fundamentals, not an analyst target.
What is the BICO Group AB (publ) stock forecast for 2026?
Our models put fair value at $1.60, about +173% upside versus a price of $0.5871 (undervalued). Cautious scenario $1.19, optimistic scenario $1.74. The calculation is refreshed regularly with new filings.
What is the revenue of BICO Group AB (publ) (BCCOY)?
BICO Group AB (publ) reported trailing-twelve-month revenue of about $1.8B (latest available figure, as of Sep 24, 2026).
What growth is priced into BICO Group AB (publ) (BCCOY)?
For today's price to be fair in a discounted-cash-flow model, BICO Group AB (publ) would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 15.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +51.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of BCCOY use?
Our models discount BICO Group AB (publ) at 15.2 %: a base by market capitalisation (micro), damped by beta 2.55, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BICO Group AB (publ) that is less than minus 40 % per year a year over ten years, using the same discount rate (15.2 %) and the same formula as our fair value.
How much growth has BICO Group AB (publ) (BCCOY) delivered so far?
Over the past 5 years revenue at BICO Group AB (publ) grew +51.4 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BICO Group AB (publ) (BCCOY) growing?
The median revenue growth in the sector is +4.1 % a year. That is the yardstick for the growth priced into BICO Group AB (publ) (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BICO Group AB (publ) (BCCOY)?
The free-cash-flow yield on the price is 31.25 %: that much free cash flow BICO Group AB (publ) produces per unit of market value. When it exceeds the discount rate of our models (15.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BICO Group AB (publ) (BCCOY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BICO Group AB (publ) it is $1.60 per share (as of Sep 24, 2026), against a price of $0.5871. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is BICO Group AB (publ) stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BCCOY trades below its calculated fair value: price $0.5871, fair value $1.60, a gap of about +173% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BCCOY?
No. The price is what the market pays today ($0.5871); the fair value is what the company's own numbers justify ($1.60). For BICO Group AB (publ) the two are $1.01 per share apart. That gap is exactly why we show both numbers side by side.
How much is BICO Group AB (publ) worth?
The market values BICO Group AB (publ) at about $166M (market capitalisation, as of Sep 24, 2026). Per share that is $0.5871; our models calculate a fair value of $1.60 per share.
What do the bullish and bearish scenarios say about BCCOY?
Our models span a range for BICO Group AB (publ): cautious scenario $1.19, base $1.60, optimistic $1.74 per share (as of Sep 24, 2026, price $0.5871). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BICO Group AB (publ) (BCCOY)?
Balance-sheet figures for BICO Group AB (publ) (as of Sep 24, 2026): return on equity −69.3%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is BCCOY from its 52-week high?
BICO Group AB (publ) trades at $0.5871, about 41% below its 52-week high of $1.00 and 57% above the low of $0.3750 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $1.60 is for.
Which stocks are comparable to BICO Group AB (publ)?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BICO Group AB (publ) stock attractive at the current price?
The data as of Sep 24, 2026: price $0.5871, calculated fair value $1.60 (+173%), Quality Score 50/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BCCOY calculated?
We run BICO Group AB (publ) through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.60, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. BICO Group AB (publ) currently trades 173 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BICO Group AB (publ) (BCCOY)?
The closing price on Sep 18, 2026 was $0.5871. Our model-based fair value is $1.60, about +173% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BICO Group AB (publ) right now?
The price is below even our cautious bear case ($1.19). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of BICO Group AB (publ)

How large is the market capitalisation of BICO Group AB (publ) (BCCOY)?
The market capitalisation of BICO Group AB (publ) is $166M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BICO Group AB (publ) (BCCOY)?
The price-to-sales ratio of BICO Group AB (publ) is 0.08 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BICO Group AB (publ) (BCCOY)?
Earnings per share at BICO Group AB (publ) are $−0.5600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BICO Group AB (publ) (BCCOY)?
The net margin of BICO Group AB (publ) is −72.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BICO Group AB (publ) (BCCOY)?
The return on equity (ROE) of BICO Group AB (publ) is −69.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BICO Group AB (publ) (BCCOY)?
On an EBIT basis the return on assets of BICO Group AB (publ) is −4.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at BICO Group AB (publ) (BCCOY)?
Revenue at BICO Group AB (publ) is growing −1.4% versus a year earlier (3y avg −14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does BICO Group AB (publ) (BCCOY) carry?
The net debt of BICO Group AB (publ) is $223M (fiscal year 2025, ≈ 4.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch BICO Group AB (publ) in the live analysis

One click puts BICO Group AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.